Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and Advanz Pharma submitted AVT29, a proposed biosimilar to Eylea 8 mg, to the European Medicines Agency as a line extension to Mynzepli’s existing authorization; the companies say this is the first worldwide regulatory submission for a proposed Eylea 8 mg biosimilar. AVT29 remains investigational and is not approved. The 8 mg formulation allows 16-week treatment intervals for certain patients, versus the standard eight-week maintenance interval for the 2 mg formulation; it represented approximately 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from approximately 30% in Q2 2025.

Analysis

The economically important shift is not simply another biosimilar filing: competition is moving toward the higher-dose segment, where convenience may make the originator harder to displace than the legacy formulation. If AVT29 clears review, Alvotech/Advanz could compete for new starts and eventual switches, but launch value depends on regulatory timing, country-level reimbursement, prescriber comfort, and whether clinics can substitute without disrupting established treatment protocols. More frequent dosing may remain clinically preferable for some patients, limiting conversion.

For Regeneron and Bayer, the risk is incremental erosion of Eylea pricing and negotiating leverage in Europe, not an immediate collapse in franchise revenue. The counterweight is that a lower-cost option could expand access or slow migration to competing retinal therapies such as Roche’s Vabysmo; product-level net sales and switching data will determine which effect dominates. For Alvotech, this is a meaningful pipeline validation signal, but submission alone does not establish biosimilarity, approval, launch timing, or commercial contribution. Near-term equity impact is likely sentiment-driven; the 1–3 month catalyst path is regulatory review/clarifications, while material competitive effects are a 6–18 month question at minimum. No valuation or launch-economics data support a target price.

Key Decisions for Investors

• ALVO: Treat the announcement as a modest positive catalyst, not an earnings inflection. Prefer waiting for review milestones and evidence on launch timing, European pricing, and partner commercialization before adding exposure; the thesis is falsified by a material regulatory delay or weak uptake after launch.
• REGN / BAYN: No immediate short recommendation. Monitor European Eylea net pricing, high-dose share, and switching/substitution trends; a sustained deterioration in net price or guidance would strengthen a relative underweight thesis, while stable franchise economics would argue the threat is over-discounted.
• Watch for EMA questions or approval conditions, national reimbursement decisions, and any patent or launch-timing disclosures. These are the key missing inputs to estimate addressable sales and the speed of erosion; the press release does not establish them.
• If taking exposure, size ALVO as event-risk rather than a proven commercial ramp. A pair trade against REGN is premature until approval, launch access, and real-world conversion are clearer.